Vera Therapeutics announced inducement grants to 17 new employees on June 3, 2025. The grants include non-qualified stock options to purchase 124,000 shares of Class A common stock at $30.91 per share and RSUs for 65,925 shares. The stock options will vest over 4 years, with 25% vesting after the first year and the remainder vesting monthly over 36 months. The RSUs will vest over 4 years, with 25% vesting annually starting August 20, 2025. These awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) as inducement material for new employee employment.
Vera Therapeutics ha annunciato il 3 giugno 2025 l'assegnazione di incentivi a 17 nuovi dipendenti. Gli incentivi comprendono opzioni azionarie non qualificate per l'acquisto di 124.000 azioni di azioni ordinarie di Classe A al prezzo di 30,91 dollari per azione e RSU per 65.925 azioni. Le opzioni azionarie matureranno in 4 anni, con il 25% che matura dopo il primo anno e il restante che matura mensilmente nei successivi 36 mesi. Le RSU matureranno in 4 anni, con il 25% che matura annualmente a partire dal 20 agosto 2025. Questi premi sono stati approvati dal Comitato per la retribuzione ai sensi della Regola 5635(c)(4) del Nasdaq come incentivo materiale per l'assunzione di nuovi dipendenti.
Vera Therapeutics anunció el 3 de junio de 2025 concesiones inducidas a 17 nuevos empleados. Las concesiones incluyen opciones sobre acciones no calificadas para comprar 124,000 acciones comunes Clase A a 30.91 dólares por acción y RSU por 65,925 acciones. Las opciones sobre acciones se consolidarán en 4 años, con el 25% consolidado después del primer año y el resto consolidándose mensualmente durante los siguientes 36 meses. Las RSU se consolidarán en 4 años, con el 25% consolidado anualmente a partir del 20 de agosto de 2025. Estos premios fueron aprobados por el Comité de Compensación bajo la Regla de Cotización Nasdaq 5635(c)(4) como un incentivo material para la contratación de nuevos empleados.
Vera Therapeutics는 2025년 6월 3일에 17명의 신입 사원에게 유인 보조금을 발표했습니다. 보조금에는 주당 30.91달러에 클래스 A 보통주 124,000주를 구매할 수 있는 비공인 주식 옵션과 65,925주의 RSU가 포함되어 있습니다. 주식 옵션은 4년에 걸쳐 베스팅되며, 첫 해에 25%가 베스팅되고 나머지는 36개월 동안 매월 베스팅됩니다. RSU는 4년에 걸쳐 베스팅되며, 2025년 8월 20일부터 매년 25%씩 베스팅됩니다. 이 상여금은 신규 직원 채용을 위한 유인 자료로서 Nasdaq 상장 규칙 5635(c)(4)에 따라 보상 위원회의 승인을 받았습니다.
Vera Therapeutics a annoncé le 3 juin 2025 l'attribution de primes d'incitation à 17 nouveaux employés. Ces primes comprennent des options d'achat d'actions non qualifiées pour acquérir 124 000 actions ordinaires de classe A au prix de 30,91 $ par action et des RSU pour 65 925 actions. Les options d'achat d'actions seront acquises sur 4 ans, avec 25 % acquises après la première année et le reste acquis mensuellement sur 36 mois. Les RSU seront acquises sur 4 ans, avec 25 % acquis annuellement à partir du 20 août 2025. Ces attributions ont été approuvées par le comité de rémunération conformément à la règle 5635(c)(4) du Nasdaq en tant qu'incitation matérielle à l'embauche de nouveaux employés.
Vera Therapeutics gab am 3. Juni 2025 Anreizzuwendungen für 17 neue Mitarbeiter bekannt. Die Zuwendungen umfassen nicht qualifizierte Aktienoptionen zum Kauf von 124.000 Aktien der Klasse A zu einem Preis von 30,91 USD pro Aktie und RSUs für 65.925 Aktien. Die Aktienoptionen werden über 4 Jahre vesten, wobei 25 % nach dem ersten Jahr vesten und der Rest monatlich über 36 Monate. Die RSUs vesten über 4 Jahre, mit 25 % jährlich beginnend am 20. August 2025. Diese Auszeichnungen wurden vom Vergütungsausschuss gemäß Nasdaq-Listing-Regel 5635(c)(4) als wesentliche Anreize für die Einstellung neuer Mitarbeiter genehmigt.
Positive
Company is expanding its workforce with 17 new employees
Structured equity compensation plan helps align employee interests with shareholders
Negative
Potential dilution of existing shareholders from new equity grants
BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on June 3, 2025 has an exercise price per share equal to $30.91, Vera’s closing trading price on June 3, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of August 20, 2025, subject to the new employee’s continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About Vera Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit www.veratx.com.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
